Publicacións en colaboración con investigadores/as de McGill University Health Centre (5)

2024

  1. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

    JACC: Cardiovascular Interventions, Vol. 17, Núm. 3, pp. 374-387

2022

  1. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

    Nature Medicine, Vol. 28, Núm. 12, pp. 2512-2520

2021

  1. Empagliflozin in heart failure with a preserved ejection fraction

    New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461

2020

  1. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

    European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392

2008

  1. Benefit of neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction

    Transplantation, Vol. 85, Núm. 7, pp. 992-999